Ewan C Goligher, Patrick R Lawler, Thomas P Jensen, Victor Talisa, Lindsay R Berry, Elizabeth Lorenzi, Bryan J McVerry, Chung-Chou Ho Chang, Eric Leifer, Charlotte Bradbury, Jeffrey Berger, Beverly J Hunt, Lana A Castellucci, Lucy Z Kornblith, Anthony C Gordon, Colin McArthur, Steven Webb, Judith Hochman, Matthew D Neal, Ryan Zarychanski, Scott Berry, Derek C Angus
IMPORTANCE: Randomized clinical trials (RCTs) of therapeutic-dose heparin in patients hospitalized with COVID-19 produced conflicting results, possibly due to heterogeneity of treatment effect (HTE) across individuals. Better understanding of HTE could facilitate individualized clinical decision-making. OBJECTIVE: To evaluate HTE of therapeutic-dose heparin for patients hospitalized for COVID-19 and to compare approaches to assessing HTE. DESIGN, SETTING, AND PARTICIPANTS: Exploratory analysis of a multiplatform adaptive RCT of therapeutic-dose heparin vs usual care pharmacologic thromboprophylaxis in 3320 patients hospitalized for COVID-19 enrolled in North America, South America, Europe, Asia, and Australia between April 2020 and January 2021...
March 21, 2023: JAMA